Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more
Shanghai Kaibao Pharmaceutical (300039) - Net Assets
Latest net assets as of September 2025: CN¥4.55 Billion CNY
Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) has net assets worth CN¥4.55 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.96 Billion) and total liabilities (CN¥412.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.55 Billion |
| % of Total Assets | 91.68% |
| Annual Growth Rate | 29.85% |
| 5-Year Change | 59.14% |
| 10-Year Change | 104.59% |
| Growth Volatility | 181.63 |
Shanghai Kaibao Pharmaceutical - Net Assets Trend (2006–2024)
This chart illustrates how Shanghai Kaibao Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Kaibao Pharmaceutical (2006–2024)
The table below shows the annual net assets of Shanghai Kaibao Pharmaceutical from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.10 Billion | +1.74% |
| 2023-12-31 | CN¥4.03 Billion | +7.23% |
| 2022-12-31 | CN¥3.76 Billion | +23.52% |
| 2021-12-31 | CN¥3.04 Billion | +18.10% |
| 2020-12-31 | CN¥2.58 Billion | +0.34% |
| 2019-12-31 | CN¥2.57 Billion | +3.39% |
| 2018-12-31 | CN¥2.49 Billion | +5.06% |
| 2017-12-31 | CN¥2.37 Billion | +7.51% |
| 2016-12-31 | CN¥2.20 Billion | +9.71% |
| 2015-12-31 | CN¥2.01 Billion | +6.41% |
| 2014-12-31 | CN¥1.88 Billion | +17.34% |
| 2013-12-31 | CN¥1.61 Billion | +13.20% |
| 2012-12-31 | CN¥1.42 Billion | +6.32% |
| 2011-12-31 | CN¥1.33 Billion | +7.88% |
| 2010-12-31 | CN¥1.24 Billion | +7.92% |
| 2009-12-31 | CN¥1.15 Billion | +803.05% |
| 2008-12-31 | CN¥126.92 Million | +64.92% |
| 2007-12-31 | CN¥76.96 Million | +106.69% |
| 2006-12-31 | CN¥37.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Kaibao Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9272.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.03 Billion | 49.59% |
| Common Stock | CN¥1.05 Billion | 25.50% |
| Other Comprehensive Income | CN¥1.02 Billion | 24.91% |
| Total Equity | CN¥4.10 Billion | 100.00% |
Shanghai Kaibao Pharmaceutical Competitors by Market Cap
The table below lists competitors of Shanghai Kaibao Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gas Malaysia Bhd
KLSE:5209
|
$532.26 Million |
|
Xiamen Jihong Package Technology Ltd
SHE:002803
|
$532.29 Million |
|
Quanta Storage
TWO:6188
|
$532.29 Million |
|
Ethan Allen Interiors Inc
NYSE:ETD
|
$532.41 Million |
|
Acrobiosystems Co.Ltd.
SHE:301080
|
$532.16 Million |
|
Family Zone Cyber Safety Limited
PINK:FMZNF
|
$532.06 Million |
|
Qinhuangdao Port Co Ltd
SHG:601326
|
$531.99 Million |
|
SP Setia Bhd
KLSE:8664
|
$531.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Kaibao Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,031,217,457 to 4,102,051,563, a change of 70,834,106 (1.8%).
- Net income of 375,578,025 contributed positively to equity growth.
- Dividend payments of 104,636,997 reduced retained earnings.
- Other comprehensive income increased equity by 95,409,249.
- Other factors decreased equity by 295,516,171.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥375.58 Million | +9.16% |
| Dividends Paid | CN¥104.64 Million | -2.55% |
| Other Comprehensive Income | CN¥95.41 Million | +2.33% |
| Other Changes | CN¥-295.52 Million | -7.2% |
| Total Change | CN¥- | 1.76% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Kaibao Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 19.63x to 1.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.32 | CN¥6.26 | x |
| 2007-12-31 | CN¥0.64 | CN¥6.26 | x |
| 2008-12-31 | CN¥0.16 | CN¥6.26 | x |
| 2009-12-31 | CN¥1.43 | CN¥6.26 | x |
| 2010-12-31 | CN¥1.16 | CN¥6.26 | x |
| 2011-12-31 | CN¥1.26 | CN¥6.26 | x |
| 2012-12-31 | CN¥1.33 | CN¥6.26 | x |
| 2013-12-31 | CN¥1.50 | CN¥6.26 | x |
| 2014-12-31 | CN¥1.76 | CN¥6.26 | x |
| 2015-12-31 | CN¥1.85 | CN¥6.26 | x |
| 2016-12-31 | CN¥2.05 | CN¥6.26 | x |
| 2017-12-31 | CN¥2.21 | CN¥6.26 | x |
| 2018-12-31 | CN¥2.35 | CN¥6.26 | x |
| 2019-12-31 | CN¥2.46 | CN¥6.26 | x |
| 2020-12-31 | CN¥2.46 | CN¥6.26 | x |
| 2021-12-31 | CN¥2.91 | CN¥6.26 | x |
| 2022-12-31 | CN¥3.60 | CN¥6.26 | x |
| 2023-12-31 | CN¥3.85 | CN¥6.26 | x |
| 2024-12-31 | CN¥3.92 | CN¥6.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Kaibao Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.16%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.49%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.10x
- Recent ROE (9.16%) is below the historical average (17.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 56.04% | 12.54% | 1.53x | 2.93x | CN¥17.14 Million |
| 2007 | 59.68% | 17.36% | 1.60x | 2.15x | CN¥37.30 Million |
| 2008 | 45.42% | 14.88% | 1.69x | 1.81x | CN¥44.96 Million |
| 2009 | 5.99% | 14.96% | 0.34x | 1.17x | CN¥-45.95 Million |
| 2010 | 10.00% | 20.50% | 0.44x | 1.11x | CN¥-1.02K |
| 2011 | 12.56% | 20.44% | 0.56x | 1.09x | CN¥34.12 Million |
| 2012 | 17.07% | 21.98% | 0.71x | 1.10x | CN¥100.31 Million |
| 2013 | 19.85% | 24.09% | 0.75x | 1.10x | CN¥158.21 Million |
| 2014 | 18.54% | 23.59% | 0.70x | 1.12x | CN¥160.89 Million |
| 2015 | 14.04% | 20.18% | 0.58x | 1.21x | CN¥81.10 Million |
| 2016 | 12.84% | 18.88% | 0.59x | 1.15x | CN¥62.58 Million |
| 2017 | 11.51% | 17.35% | 0.59x | 1.13x | CN¥35.76 Million |
| 2018 | 9.13% | 15.11% | 0.55x | 1.11x | CN¥-21.70 Million |
| 2019 | 9.77% | 17.69% | 0.50x | 1.11x | CN¥-5.96 Million |
| 2020 | 4.12% | 11.69% | 0.32x | 1.12x | CN¥-151.71 Million |
| 2021 | 4.60% | 12.73% | 0.33x | 1.10x | CN¥-164.38 Million |
| 2022 | 5.07% | 17.05% | 0.26x | 1.13x | CN¥-185.37 Million |
| 2023 | 8.13% | 20.57% | 0.35x | 1.14x | CN¥-75.25 Million |
| 2024 | 9.16% | 25.49% | 0.33x | 1.10x | CN¥-34.63 Million |
Industry Comparison
This section compares Shanghai Kaibao Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Kaibao Pharmaceutical (300039) | CN¥4.55 Billion | 56.04% | 0.09x | $532.26 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |